GB-0895
Long-acting anti-TSLP antibody for severe asthma, advancing to Phase 3.
Executive Summary
GB-0895 is a novel, long-acting anti-TSLP (thymic stromal lymphopoietin) antibody developed by Generate Biomedicines for the treatment of severe asthma. This therapeutic candidate leverages Generate Biomedicines' proprietary machine learning-powered generative biology platform for its design and optimization. The drug is engineered to provide sustained therapeutic benefits by targeting the TSLP pathway, a key mediator in asthma pathogenesis. Having successfully completed Phase 1 clinical studies, GB-0895 has demonstrated promising safety and pharmacokinetic profiles. Generate Biomedicines is now preparing to initiate global Phase 3 clinical trials to further evaluate its efficacy and safety in a broader population of patients suffering from severe asthma. This advancement underscores the potential of generative AI in accelerating the discovery and development of innovative biologic medicines.
Use Cases
- Treating severe asthma patients requiring long-acting therapy.
- Modulating the TSLP pathway to reduce asthma exacerbations and symptoms.
- Providing a novel biologic option for patients inadequately controlled by existing treatments.
- Advancing generative AI-designed therapeutics through late-stage clinical development.
Features
Intelligence
- AI-Driven Protein Design: Utilizes generative AI models to create novel protein structures and sequences, such as the anti-TSLP antibody GB-0895, with desired therapeutic properties.
- Multimodality Platform: Integrates diverse biological data and computational methods to accelerate the discovery and optimization of biologics.
- Targeted Therapeutic Development: Focuses on designing highly specific antibodies to address key disease pathways, like TSLP in severe asthma.
Technical Specifications
- Architecture
- Machine learning-powered generative biology platform
AI/ML Stack
- Generative AI
- Machine Learning
- Deep Learning (Chroma)
- Generative Biology
About Generate Biomedicines
Generate Biomedicines is a therapeutics company pioneering generative biology at the intersection of machine learning, biological engineering, and medicine to create breakthrough medicines. It operates as a developer of a machine learning-powered biomedicines platform with the potential to generate new drugs across a wide range of biologic modalities.
Alternatives to GB-0895
- GB-7624 by Generate Biomedicines — Anti-IL-13 therapeutic for atopic dermatitis, entering Phase 1 trial in early 2025.
- Geneious Biologics by Dotmatics — Accelerate antibody discovery with cloud-based screening, analysis, and visualization.
- Generate Platform by Generate Biomedicines — Pioneering generative biology to create breakthrough medicines with AI.
- Generative Biologics by Insilico Medicine — AI-powered platform for generative design and optimization of biologics.
- inClinico by Insilico Medicine — Generative AI-powered platform for data-driven, multimodal prediction of clinical trial outcomes.
- Insitro Platform by Insitro — Machine Learning to Unravel Biology and Redefine Disease for Better Drugs, Faster.
- iPSC-based disease modeling by Evotec — Leveraging iPSCs for advanced disease modeling in drug discovery.
- Isomorphic Labs Platform by Isomorphic Labs — Harnessing AI to unlock deeper scientific insights for life-changing medicines.